Serum Levels of the Bone Turnover Markers Dickkopf-1, Sclerostin, Osteoprotegerin, Osteopontin, Osteocalcin and 25-hydroxyvitamin D in Swedish Geriatric Patients Aged 75 years or Older with a Fresh Hip Fracture and in Healthy Controls
Overview
Authors
Affiliations
Background: Bone turnover markers have a potential clinical use in describing bone remodeling and in predicting fractures.
Aims: In an elderly population ≥75 years with a fresh hip fracture, and in healthy controls, investigate bone turnover markers and their relation to each other, to vitamin D status and to bone mineral density (BMD).
Methods: In a cross-sectional study serum levels of dickkopf-1 (DKK-1), sclerostin (SOST), osteoprotegerin (OPG), osteopontin (OPN), osteocalcin, 25-hydroxyvitamin D (25(OH)D) were analyzed in 89 Swedish patients with a fresh hip fracture and in 82 healthy volunteers. Serum levels of bone markers were determined by Luminex technique.
Results: S-25-hydroxyvitamin D (S-25(OH)D) was decreased in patients compared to controls (48 ± 21 vs. 76 ± 25 nmol/L, p < 0.001). SOST, but none of the other bone turnover markers correlated with BMD (r = 0.50, p < 0.001). Compared with controls, higher levels of OPG (488 ± 1.4 vs. 191 ± 1.4 ng/L, p < 0.001), OPN (69 ± 1.7 vs. 19 ± 1.4 µg/L, p < 0.001), DKK-1 (273 ± 1.7 vs. 168 ± 1.7 ng/L, p < 0.001), and lower levels of osteocalcin (5.8 ± 3.5 vs. 9.5 ± 3.6 µg/L, p < 0.001), were found in the fracture group. Levels of OPG, DKK-1 and SOST in both groups were positively associated. S-25(OH)D concentration was not found to be strongly associated with any of the bone markers.
Conclusions: In contrast to findings in other studies, we found no strong correlation between 25(OH)D and the investigated bone markers. Both in patients with a fresh hip fracture and in healthy elderly, DKK-1, SOST and OPG appear to be associated. This suggests a relevance in these relationships meriting further investigation.
Role of sclerostin in mastocytosis bone disease.
Szudy-Szczyrek A, Mlak R, Pigon-Zajac D, Krupski W, Mazurek M, Tomczak A Sci Rep. 2025; 15(1):161.
PMID: 39747949 PMC: 11697018. DOI: 10.1038/s41598-024-83851-0.
Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.
Halupczok-Zyla J, Jawiarczyk-Przybylowska A, Bolanowski M Front Endocrinol (Lausanne). 2025; 15:1472680.
PMID: 39741885 PMC: 11685073. DOI: 10.3389/fendo.2024.1472680.
Martiniakova M, Mondockova V, Kovacova V, Babikova M, Zemanova N, Biro R Diabetol Metab Syndr. 2024; 16(1):217.
PMID: 39238022 PMC: 11378428. DOI: 10.1186/s13098-024-01440-7.
Cianferotti L, Bifolco G, Caffarelli C, Mazziotti G, Migliaccio S, Napoli N Nutrients. 2024; 16(11).
PMID: 38892706 PMC: 11174536. DOI: 10.3390/nu16111773.
Li W, Wang W, Zhang M, Chen Q, Li F, Li S BMC Endocr Disord. 2024; 24(1):55.
PMID: 38679740 PMC: 11056049. DOI: 10.1186/s12902-024-01591-8.